A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
List view / Grid view
Filter the results
The UK MHRA has given a positive scientific opinion for Merck and Pfizer's avelumab on the Early Access to Medicines Scheme (EAMS).
Immunotherapy drug plus targeted agent provided better progression-free survival and shrank tumors in more patients than standard one-drug treatment...